Skip to main content

Toggle search

Home
Company
About us

Board of Directors

Management team

Corporate Responsibility
Technologies
Circassia Technologies

Particle-engineered respiratory therapies

Our proprietary particle-engineering technologies underpin a portfolio of respiratory product candidates for which we are seeking development partners.

NIOX® FeNO testing

Our NIOX® products accurately measure the concentration of fractional exhaled nitric oxide (FeNO) in asthma patients’ breath to help evaluate underlying airway inflammation.
Technologies
Products
Pipeline
Pipeline Products

Asthma therapies
Flixotide® / Flovent® substitute
Seretide® substitute
COPD treatments
Duaklir® US
Spiriva® substitute
Novel LABA / LAMA formulation & novel COPD therapy formulation
AirNOvent
AirNOvent
Pipeline chart

Commercial opportunity
Investors
Regulatory news

Share price summary

Share price chart

Analyst coverage

Financial reports

Financial calendar

Registrars

AIM rule 26

Warning to shareholders

Email alerts

Investor contacts

Historic transactions
Careers
Career Opportunities

UK Opportunities
US Opportunities
European Opportunities
China Opportunities
Opportunities

Job Applicant Privacy Notice

Careers contacts
Media
Latest Press Release

Circassia Announces FDA Approval of Duaklir® for Maintenance Treatment of Chronic Obstructive Pulmonary Disease
1st April 2019
Press releases

Presentations

Webcasts & audio

Image library

Media contacts
Contacts
Locations

Departments

Conferences

Investors

Regulatory news
Share price summary
Share price chart
Analyst coverage
Financial reports
Financial calendar
Registrars
AIM rule 26
Warning to shareholders
Email alerts
Investor contacts
Historic transactions

Historic transactions

Click on the download links below to access our documentation.

© 2019 Circassia. All Rights Reserved.

Legal notice
Privacy Policy
Privacy shield policy
Cookie Settings
Site map